

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|  |           |  |
|--|-----------|--|
| <b>(51) International Patent Classification <sup>6</sup> :</b><br><b>A61K 35/22</b>  | <b>A1</b> | <b>(11) International Publication Number:</b> <b>WO 96/31225</b><br><b>(43) International Publication Date:</b> 10 October 1996 (10.10.96)   |
| <b>(21) International Application Number:</b> PCT/US96/02360<br><b>(22) International Filing Date:</b> 22 February 1996 (22.02.96)<br><br><b>(30) Priority Data:</b><br>08/418,763                      7 April 1995 (07.04.95)                      US<br><br><b>(71) Applicant:</b> PURDUE RESEARCH FOUNDATION [US/US];<br>Room 328, 1650 Engineering Administration Building, West<br>Lafayette, IN 47907-1650 (US).<br><br><b>(72) Inventors:</b> BADYLAK, Stephen, F.; 2610 Nottingham Place,<br>West Lafayette, IN 47906 (US). VOYTIK, Sherry, L.; 113<br>Red Cloud Trail #905, Lafayette, IN 47905 (US). BRIGHT-<br>MAN, Andrew; 133 Prophet Drive, West Lafayette, IN<br>47906 (US). WANINGER, Matt; 1059 Forest Drive, Frank-<br>fort, IN 46041 (US).<br><br><b>(74) Agents:</b> LAMMERT, Steven, R. et al.; Barnes & Thornburg,<br>1313 Merchants Bank Building, 11 South Meridian Street,<br>Indianapolis, IN 46204 (US). |           | <b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BB, BG, BR, BY,<br>CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS,<br>JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD,<br>MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD,<br>SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO<br>patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AZ,<br>BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,<br>CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT,<br>SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML,<br>MR, NE, SN, TD, TG).<br><br><b>Published</b><br><i>With international search report.</i> |
| <b>(54) Title:</b> URINARY BLADDER SUBMUCOSA DERIVED TISSUE GRAFT<br><br><b>(57) Abstract</b><br><br>A tissue graft composition comprising bladder submucosal tissue delaminated from abluminal muscle layers and at least the luminal portion of the tunica mucosa of a segment of vertebrate urinary bladder is described. The graft composition can be implanted to replace or support damaged or diseased tissues.   |           |  |

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |  |    |                          |
|----|--------------------------|----|--|----|--------------------------|
| AM | Armenia                  | GB | United Kingdom                           | MW | Malawi                   |
| AT | Austria                  | GE | Georgia                                  | MX | Mexico                   |
| AU | Australia                | GN | Guinea                                   | NE | Niger                    |
| BB | Barbados                 | GR | Greece                                   | NL | Netherlands              |
| BE | Belgium                  | HU | Hungary                                  | NO | Norway                   |
| BF | Burkina Faso             | IE | Ireland                                  | NZ | New Zealand              |
| BG | Bulgaria                 | IT | Italy                                    | PL | Poland                   |
| BJ | Benin                    | JP | Japan                                    | PT | Portugal                 |
| BR | Brazil                   | KE | Kenya                                    | RO | Romania                  |
| BY | Belarus                  | KG | Kyrgyzstan                               | RU | Russian Federation       |
| CA | Canada                   | KP | Democratic People's Republic<br>of Korea | SD | Sudan                    |
| CF | Central African Republic | KR | Republic of Korea                        | SE | Sweden                   |
| CG | Congo                    | KZ | Kazakhstan                               | SG | Singapore                |
| CH | Switzerland              | LI | Liechtenstein                            | SI | Slovenia                 |
| CI | Côte d'Ivoire            | LK | Sri Lanka                                | SK | Slovakia                 |
| CM | Cameroon                 | LR | Liberia                                  | SN | Senegal                  |
| CN | China                    | LT | Lithuania                                | SZ | Swaziland                |
| CS | Czechoslovakia           | LU | Luxembourg                               | TD | Chad                     |
| CZ | Czech Republic           | LV | Latvia                                   | TG | Togo                     |
| DE | Germany                  | MC | Monaco                                   | TJ | Tajikistan               |
| DK | Denmark                  | MD | Republic of Moldova                      | TT | Trinidad and Tobago      |
| EE | Estonia                  | MG | Madagascar                               | UA | Ukraine                  |
| ES | Spain                    | ML | Mali                                     | UG | Uganda                   |
| FI | Finland                  | MN | Mongolia                                 | US | United States of America |
| FR | France                   | MR | Mauritania                               | UZ | Uzbekistan               |
| GA | Gabon                    |    |  | VN | Viet Nam                 |

-1-

URINARY BLADDER SUBMUCOSA DERIVED TISSUE GRAFTField of the Invention

5 The present invention relates to a tissue graft composition and methods for its preparation and use. More particularly, the present invention is directed to non-immunogenic tissue graft compositions comprising urinary bladder submucosa and use of same to promote endogenous tissue growth.

10

Background and Summary of the Invention

It is known that compositions comprising the tunica submucosa of the intestine of warm-blooded vertebrates can be used advantageously as tissue graft materials. See U.S. Patent Nos. 4,902,508 and 5,281,422. The tissue graft compositions described in those patents are characterized by excellent mechanical properties, including high compliance, a high burst pressure point, and an effective porosity index which allows such compositions to be used beneficially for vascular graft and connective tissue graft constructs. When used in such applications the graft constructs appear not only to serve as a matrix for the regrowth of the tissues replaced by the graft constructs, but, indeed, to promote or induce such regrowth of endogenous tissue. Common events to this remodeling process include: widespread and very rapid neovascularization, proliferation of granulation mesenchymal cells, biodegradation/resorption of implanted intestinal submucosal tissue material, and lack of immune rejection.

30

It is also known that intestinal submucosa can be fluidized by comminuting and/or protease digestion, without loss of its apparent biotropic properties, for use in less invasive methods of administration (e.g., by injection or

-2-

topical application) to host tissues in need of repair.  
See U.S. Patent No. 5,275,826.

There has been much additional research effort directed to finding other natural and synthetic materials having the requisite properties for use as tissue grafts. Surprisingly, it has been found that urinary bladder submucosa (UBS) prepared by delamination of bladder tissue of warm-blooded vertebrates exhibits mechanical and biotropic properties similar to that which has been reported for intestinal submucosal tissue. It can be substituted for intestinal submucosa tissue in most, if not all, of the applications previously reported for intestinal submucosa.

The tissue graft composition of the present invention comprises urinary bladder submucosa derived from urinary bladder tissue of a warm-blooded vertebrate. The wall of the urinary bladder is composed of the following layers: the tunica mucosa (including a transitional epithelium layer and the tunica propria), a submucosa layer, up to three layers of muscle and the adventitia (a loose connective tissue layer) - listed in thickness crosssection from luminal to abluminal sides. Urinary bladder submucosa for use in accordance with the present invention is delaminated from the abluminal muscle layers and at least the luminal portion of the tunica mucosa of the urinary bladder tissue. The present graft composition can be implanted or injected into a vertebrate host to induce the repair or replacement of damaged or defective tissues.

30

#### Detailed Description of the Invention

The tissue graft composition in accordance with the present invention comprises urinary bladder submucosa of a warm-blooded vertebrate delaminated from adjacent bladder tissue layers. The present tissue graft

35

-3-

composition thus comprises the bladder submucosa delaminated from abluminal muscle cell layers and at least the luminal portion of the mucosal layer of a segment of urinary bladder of a warm-blooded vertebrate. Typically  
5 the delamination technique described below provides a tissue composition consisting essentially of urinary bladder submucosa. These compositions are referred to herein generically as urinary bladder submucosa (UBS).

UBS graft material is typically prepared from  
10 bladder tissue harvested from animals raised for meat production, including, for example, pigs, cattle and sheep or other warm-blooded vertebrates. Thus, there is an inexpensive commercial source of urinary bladder tissue for use in preparation of the tissue compositions in accordance  
15 with the present invention.

The preparation of UBS from a segment of urinary bladder is similar to the procedure for preparing intestinal submucosa detailed in U.S. Patent No. 4,902,508, the disclosure of which is expressly incorporated herein by  
20 reference. A segment of urinary bladder tissue is first subjected to abrasion using a longitudinal wiping motion to remove both the outer layers (particularly the abluminal smooth muscle layers) and the luminal portions of the tunica mucosa layers - the epithelial layers). The  
25 resulting submucosa tissue has a thickness of about 80 micrometers, and consists primarily (greater than 98%) of acellular, eosinophilic staining (H&E stain) extracellular matrix material. Occasional blood vessels and spindle cells consistent with fibrocytes are scattered randomly  
30 throughout the tissue. Typically the UBS is rinsed with saline and optionally stored in a frozen hydrated state until used as described below.

Fluidized UBS can be prepared in a manner similar to the preparation of fluidized intestinal submucosa, as  
35 described in U.S. Patent No. 5,275,826 the disclosure of

-4-

which is expressly incorporated herein by reference. The UBS is comminuted by tearing, cutting, grinding, shearing and the like. Grinding the UBS in a frozen or freeze-dried state is preferred although good results can be obtained as well by subjecting a suspension of submucosa pieces to treatment in a high speed (high shear) blender and dewatering, if necessary, by centrifuging and decanting excess water. Additionally, the comminuted fluidized tissue can be solubilized by enzymatic digestion of the bladder submucosa with a protease, such as trypsin or pepsin, or other appropriate enzymes for a period of time sufficient to solubilize said tissue and form a substantially homogeneous solution.

The present invention also contemplates the use of powder forms of UBS. In one embodiment a powder form of UBS is prepared by pulverizing urinary bladder submucosa tissue under liquid nitrogen to produce particles ranging in size from 0.1 to 1 mm<sup>2</sup>. The particulate composition is then lyophilized overnight and sterilized to form a solid substantially anhydrous particulate composite. Alternatively, a powder form of UBS can be formed from fluidized UBS by drying the suspensions or solutions of comminuted UBS.

The UBS tissue compositions of the present invention lend themselves to a wide variety of surgical applications relating to the repair or replacement of damaged tissues, including, for example the repair of vascular and connective tissues. Connective tissues for the purposes of the present invention includes bone, cartilage, muscle, tendons, ligaments, and fibrous tissue including the dermal layer of skin.

In accordance with the present invention, the graft compositions of the present invention are used advantageously to induce the formation of endogenous tissue at a desired site in a warm blooded vertebrate.

-5-

Compositions comprising urinary bladder submucosa can be administered to a vertebrate host in an amount effective to induce endogenous tissue growth at a site in the host in need of same due to the presence of damaged or diseased tissue. The UBS compositions can be administered to the host in either solid or sheet form, by surgical implantation, or in fluidized form, by injection.

In one embodiment the present UBS compositions in sheet form can be used to form vascular grafts. The diameter of the graft should be about the same as the diameter of the recipient blood vessel. This is accomplished by manipulating the UBS to define a cylinder having diameter approximately the same as that of the recipient blood vessel and suturing or otherwise securing the tissue graft longitudinally to form said vascular graft. Thus, for example, a vascular graft can be prepared by selecting a sterile glass rod having an outer diameter equal to that of the recipient blood vessel, wrapping the UBS sheet around the glass rod and gathering the redundant tissue. The desired lumen diameter is achieved by suturing along the length of the graft (for example, using two continuous suture lines or a simple interrupted suture line) or by using other art-recognized tissue securing techniques. The vascular graft is surgically substituted for a damaged or diseased blood vessel using standard vascular surgery techniques.

Consistent with the use of UBS as a vascular graft material, UBS possesses mechanical properties highly desirable for such tissue graft materials, including low porosity index, high compliance, and a high burst pressure point. Those skilled in the art will appreciate that vascular graft material must be of low enough porosity to prevent intraoperative hemorrhage and yet of high enough porosity to allow extension of a newly-developed vasa vasorum through the graft material to nourish the luminal

-6-

surface. Porosity of a graft material is typically measured in terms of ml of water passed per  $\text{cm}^2\text{min}^{-1}$  at a pressure of 120 mm Hg. UBS has a differential porosity to deionized water at 120 mm Hg pressure. The "porosity index" for UBS from the luminal toward abluminal direction is approximately 6.0; whereas the porosity index in the opposite direction is approximately 50. This property of differential porosity has also been noted for intestinal submucosal tissue but the values are an order of magnitude less than those values for UBS.

The UBS segments can also be used in accordance with this invention as a tissue graft construct for use in the repair or replacement of connective tissues using the same procedures described for use of intestinal submucosa in U.S. Patent Nos. 5,281,422 and 5,352,463, expressly incorporated herein by reference. The UBS composition can be used in its delaminated natural sheet form or it can be cut longitudinally or laterally to form elongated tissue segments. Such segments or sheets have an intermediate portion, and opposite end portions and opposite lateral portions which can be formed for surgical attachment to existing physiological structures, using surgically acceptable techniques.

The grafts formed and used in accordance with this invention, upon implantation, undergo biological remodelling. They serve as a rapidly vascularized matrix for support and growth of new endogenous connective tissue. When used as a tissue graft material UBS has been found to be trophic for host tissues with which it is attached or otherwise associated in its implanted environment. The graft material has been found to be remodelled (resorbed and replaced with autogenous differentiated tissue) to assume the characterizing features of the tissue(s) with which it is associated at the site of implantation. In tendon and ligament replacement studies the graft appears



-7-

to develop a surface that is synovialized. Additionally, the boundaries between the graft and endogenous tissue are no longer discernible. Indeed, where a single graft "sees" multiple microenvironments as implanted, it is  
5 differentially remodeled along its length. Thus, for example, when used in cruciate ligament replacement experiments, not only does the portion of the graft traversing the joint become vascularized and actually grow to look and function like the original ligament, but the  
10 portion of the graft in the femoral and tibial bone tunnels rapidly incorporates into and promotes development of the cortical and cancellous bone in those tunnels.

For tendon and ligament replacement applications, and other connective tissue repair applications UBS graft  
15 constructs are typically preconditioned by stretching longitudinally to a length longer than the length of the urinary bladder submucosa from which the graft construct was formed. One method of "pre-conditioning" involves application of a given load to the urinary bladder  
20 submucosa for three to five cycles. Each cycle consists of applying a load to the graft material for five seconds, followed by a ten second relaxation phase. Three to five cycles produces a stretch-conditioned graft material with reduced strain. The graft material does not return to its  
25 original size; it remains in a "stretched" dimension. For example, a UBS segment can be conditioned by suspending a weight from said segment, for a period of time sufficient to allow about 10 to about 20% or more elongation of the tissue segment. Optionally, the graft material can be  
30 preconditioned by stretching in the lateral dimension. The graft material exhibits similar viscoelastic properties in the longitudinal and lateral dimensions.

The graft segment is then formed in a variety of shapes and configurations, for example, to serve as a  
35 ligament or tendon replacement or a patch for a broken or

-8-

severed tendon or ligament. Preferably, the segment is shaped and formed to have a layered or even a multilayered configuration with at least the opposite end portions and/or opposite lateral portions being formed to have  
5 multiple layers of the graft material to provide reinforcement for attachment to physiological structures, including bone, tendon, ligament, cartilage and muscle. In a ligament replacement application, opposite ends are attached using standard surgical technique to first and  
10 second bones, respectively, the bones typically being articulated as in the case of a knee joint.

The end portions of the UBS material can be formed, manipulated or shaped to be attached, for example, to a bone structure in a manner that will reduce the  
15 possibility of graft tearing at the point of attachment. Preferably the material can be folded or partially exerted to provide multiple layers for gripping, for example, with spiked washers or staples.

Alternatively, the UBS material may be folded  
20 back on itself to join the end portions to provide a first connective portion to be attached, for example, to a first bone and a bend in the intermediate portion to provide a second connective portion to be attached to a second bone articulated with respect to the first bone. For example,  
25 one of the end portions may be adapted to be pulled through a tunnel in, for example, the femur and attached thereto, while the other of the end portions may be adapted to be pulled through a tunnel in the tibia and attached thereto to provide a substitute for the natural cruciate ligament,  
30 the segment being adapted to be placed under tension between the tunnels to provide a ligament function, i.e., a tensioning and positioning function provided by a normal ligament.

The present UBS composition may be sterilized  
35 using conventional sterilization techniques including

-9-

tanning with glutaraldehyde, formaldehyde tanning at acidic pH, ethylene oxide treatment, propylene oxide treatment, gas plasma sterilization, gamma radiation, and peracetic acid sterilization. A sterilization technique which does not significantly weaken the mechanical strength and biotropic properties of the graft is preferably used. For instance, it is believed that strong gamma radiation may cause loss of strength in the graft material. Because one of the most attractive features of these intestinal submucosa grafts is their ability to induce host-remodelling responses, it is desirable not to use a sterilization approach which will detract from that property. Preferred sterilization techniques include exposing the graft to peracetic acid, low dose gamma irradiation and gas plasma sterilization; peracetic acid sterilization being the most preferred method. Typically, after the tissue graft composition has been sterilized, the composition is wrapped in a porous plastic wrap and sterilized again using electron beam or gamma irradiation sterilization techniques.

-10-

## CLAIMS:

1. A composition comprising urinary bladder submucosa delaminated from both the abluminal muscle layers  
5 and at least the luminal portion of the tunica mucosa of a segment of a urinary bladder of a warm blooded vertebrate.
2. The tissue graft composition of claim 1 wherein the urinary bladder submucosa is fluidized.
3. The tissue graft composition of claim 1 wherein  
10 the urinary bladder submucosa is digested with a protease for a period of time sufficient to solubilize the tissue and provide a substantially homogenous solution.
4. The tissue graft composition of claim 1, wherein the urinary bladder submucosa is dried and in powder form.
- 15 5. The tissue graft composition of claim 1 formed into a cylinder having a predetermined luminal diameter and sutured along the length of the cylinder.
6. The tissue graft composition of claim 1 conditioned for use as a connective tissue substitute by  
20 stretching to produce a graft construct longer than the segment of urinary bladder tissue from which it is formed.
7. A composition useful for preparation of non-immunogenic tissue grafts capable of inducing endogenous tissue growth when implanted in warm-blooded vertebrates,  
25 said composition comprising urinary bladder submucosa delaminated from both the abluminal muscle layers and at least the luminal portion of the tunica mucosa of a segment of a urinary bladder of a warm-blooded vertebrate.
8. A method for inducing the formation of endogenous  
30 tissue at a site in need of endogenous tissue growth in a warm blooded vertebrate, said method comprising transplanting a graft composition comprising urinary bladder submucosa in an amount effective to induce endogenous tissue growth at the site the composition is  
35 administered.

-11-

9. The method of claim 8, wherein the graft composition is fluidized and is administered by injection into the warm-blooded vertebrate.

10. The method of claim 8, wherein the graft  
5 composition is administered by surgically implanting the composition into the warm-blooded vertebrate.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US96/02360**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) : A61K 35/22

US CL : 424/558

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols,

U.S. : 424/558

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, CA, MEDLINE, WPIDS

search terms: bladder submucosa and tissue graft

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|-----------|--|-----------------------|
| A         | US 4,902,508 A (BADYLAK et al.) 20 February 1990, column 1.                        | 1-10                  |

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

|   |  |
|---|--|
| * Special categories of cited documents:  |  |
| *A* document defining the general state of the art which is not considered to be of particular relevance  | *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention  |
| *E* earlier document published on or after the international filing date  | *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone   |
| *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) | *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art |
| *O* document referring to an oral disclosure, use, exhibition or other means  |  |
| *P* document published prior to the international filing date but later than the priority date claimed  | *G* document member of the same patent family  |

Date of the actual completion of the international search

10 JUNE 1996

Date of mailing of the international search report

02 JUL 1996

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Authorized officer:

JEAN C. WITZ

Facsimile No. (703) 305-3230

Telephone No. (703) 308-0196